Therapy News and Research

RSS

Study shows many parents don't fully understand the finer details of biobank storage

Researchers who collect genetic samples from children for medical research need to explain the process more clearly to parents, according to a new study that suggests many parents don't fully understand the finer details about how these samples will be used and stored. The study was published in June in Genetics in Medicine.

30 Jul 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Genotype 1 is, worldwide, the most prevalent genotype of the hepatitis C virus. It accounts for around seventy percent of all hepatitis C infections.

30 Jul 2013

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

Call it therapeutic poop, if you will, but the best hope yet for an effective treatment of childhood infections with the drug-resistant bacterium C. difficile may come straight from the gut, according to recent research.

30 Jul 2013

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Rebiotix Inc. announced today that the U.S. Food and Drug Administration has approved the company's Investigational New Drug application to begin the Phase 2 clinical study of RBX2660 for the treatment of recurrent Clostridium difficile infection.

30 Jul 2013

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

The USPSTF agreed with the CDC that since most patients (75%) who are currently infected with hepatitis C were born between 1945 - 1965, and since risk-based screening has not been successful in identifying these individuals, that a one time age-based hepatitis C blood test was necessary.

29 Jul 2013

Prana announces dosing of first patient in PBT2 Phase II trial for Alzheimer’s disease

Prana Biotechnology today announced that the first patient has been dosed in the 12-month open label extension study with Alzheimer’s Disease patients participating in Prana’s Phase 2 IMAGINE trial.

29 Jul 2013

Trovagene adopts RainDance's RainDrop digital PCR system for eventual use in CLIA laboratory

Trovagene, Inc. (NASDAQ: TROV) and RainDance Technologies announced today that Trovagene has adopted RainDance's RainDropTM Digital PCR System for research and development, and for eventual use in the Trovagene CLIA laboratory.

29 Jul 2013

ALCF honors oncologist with Lectureship Award for ground-breaking work on lung cancer research

The Bonnie J. Addario Lung Cancer Foundation (ALCF) honored Tony Mok, MD, with the 2013 Addario Lectureship Award for his continued ground-breaking work for lung cancer patients, doctors and caregivers around the world. Dr. Mok, of Chinese University of Hong Kong, received the award at the 14th International Lung Cancer Congress held on July 25 in Huntington Beach, California.

29 Jul 2013

Hepatocytes from stem-cell derived human liver cells increase survival of animals with liver disease

Researchers have generated functional hepatocytes from human stem cells, transplanted them into mice with acute liver injury, and shown the ability of these stem-cell derived human liver cells to function normally and increase survival of the treated animals.

29 Jul 2013

Many women die due to Cad, yet less likely to receive preventive recommendations

Despite coronary artery disease (CAD) killing at least as many women as men each year, women are still today less likely to receive preventive recommendations, such as lipid-lowering therapy, aspirin, and lifestyle advice, than are men at a similar risk level.

29 Jul 2013

Technique for developing more targeted drugs using molecular "robots"

Many drugs such as agents for cancer or autoimmune diseases have nasty side effects because while they kill disease-causing cells, they also affect healthy cells. Now a new study has demonstrated a technique for developing more targeted drugs, by using molecular "robots" to hone in on more specific populations of cells.

29 Jul 2013

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Ligand Pharmaceuticals Incorporated partner GlaxoSmithKline announced that today, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for GSK's REVOLADE (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in adult patients with chronic hepatitis C infection, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy

26 Jul 2013

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout is a relatively common arthritic disease that affects about 4% (I in 25) of the population. It results from the deposition of uric acid in joints due to elevated blood levels and a resulting inflammation ensues which is very painful.

26 Jul 2013

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Ligand Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for its proprietary Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

26 Jul 2013

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Adaptimmune announced today that it has opened a Phase I/IIa, multiple-site, two-cohort, open-label clinical trial in ovarian cancer at Roswell Park Cancer Institute (RPCI) in Buffalo, N.Y., and City of Hope (COH) in Duarte, Calif.

26 Jul 2013

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

Updated CVD risk audit to help GPs optimise patient management is now available online

With cardiovascular disease (CVD) causing a third of all deaths in Australia, NPS MedicineWise is encouraging GPs to stay up to date with their knowledge about CVD risk assessment and therapy.

26 Jul 2013

Epigenetic changes induced by ADO therapy prevent epilepsy progression

Epilepsy is characterized by recurrent seizures that present in many different ways. In some cases epileptic patients exhibit a progressive increase in both frequency and severity of seizures. Epigenetic changes such as DNA methylation have recently been implied as an underlying cause of several neurologic disorders, including epilepsy.

26 Jul 2013

Finding could aid in delivering personalized cancer medicine based on individual's genetics

Scientists at the Princess Margaret Cancer Centre have discovered a function of the tumor suppressor gene PTEN that helps explain why certain promising therapies fail in many cancer patients, a finding that could aid in delivering tailored, personalized cancer medicine based on an individual's genetics.

26 Jul 2013

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

A Miriam Hospital researcher has joined forces with international colleagues to call for new strategies to better manage and improve assessment and treatment for hepatitis C (HCV) infection in individuals who inject drugs.

26 Jul 2013

Therapy News and Research

Study shows many parents don't fully understand the finer details of biobank storage

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Hope for treatment of childhood infections may come straight from the gut: Therapeutic poop

FDA approves Rebiotix's IND application to begin RBX2660 Phase 2 study for recurrent CDI

Hepatitis C (HCV) testing for baby boomers: an interview with Dr. Donald Jensen, Director, Center for Liver Diseases, University of Chicago

Prana announces dosing of first patient in PBT2 Phase II trial for Alzheimer’s disease

Trovagene adopts RainDance's RainDrop digital PCR system for eventual use in CLIA laboratory

ALCF honors oncologist with Lectureship Award for ground-breaking work on lung cancer research

Hepatocytes from stem-cell derived human liver cells increase survival of animals with liver disease

Many women die due to Cad, yet less likely to receive preventive recommendations

Technique for developing more targeted drugs using molecular "robots"

GlaxoSmithKline receives CHMP positive opinion for REVOLADE

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

FDA grants orphan-drug designation for Ligand’s Captisol-enabled Topiramate Injection

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Updated CVD risk audit to help GPs optimise patient management is now available online

Epigenetic changes induced by ADO therapy prevent epilepsy progression

Finding could aid in delivering personalized cancer medicine based on individual's genetics

Miriam researcher calls for new strategies to better manage, improve treatment for HCV infection

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News